ABL Bio Inc. (298380.KQ)

KRW 64700.0

(-0.31%)

EBITDA Summary of ABL Bio Inc.

ABL Bio Inc.'s latest annual EBITDA in 2023 was 2.1 Billion KRW , down -100.85% from previous year.
ABL Bio Inc.'s latest quarterly EBITDA in 2024 Q1 was -13.63 Billion KRW , up 3.26% from previous quarter.
ABL Bio Inc. reported an annual EBITDA of 6.86 Billion KRW in 2022, up 106.59% from previous year.
ABL Bio Inc. reported an annual EBITDA of -41.35 Billion KRW in 2021, up 16.74% from previous year.
ABL Bio Inc. reported a quarterly EBITDA of -10.69 Billion KRW for 2024 Q2, up 4.52% from previous quarter.
ABL Bio Inc. reported a quarterly EBITDA of N/A for 2023 FY, down -100.85% from previous quarter.

Annual EBITDA Chart of ABL Bio Inc. (2023 - 2016)

Historical Annual EBITDA of ABL Bio Inc. (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	2.1 Billion KRW	-100.85%
2022	6.86 Billion KRW	106.59%
2021	-41.35 Billion KRW	16.74%
2020	-53.46 Billion KRW	-51.85%
2019	-35.23 Billion KRW	-65.68%
2018	-115.92 Billion KRW	-153.14%
2017	-73.04 Billion KRW	-176.82%
2016	-13.16 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-13.63 Billion KRW	3.26%
2024 Q2	-10.69 Billion KRW	4.52%
2023 FY	- KRW	-100.85%
2023 Q4	-9.56 Billion KRW	-111.12%
2023 Q3	-4.53 Billion KRW	53.25%
2023 Q2	-9.69 Billion KRW	-140.79%
2023 Q1	23.75 Billion KRW	323.22%
2022 Q1	-10.15 Billion KRW	41.16%
2022 FY	- KRW	106.59%
2022 Q4	-10.64 Billion KRW	-141.62%
2022 Q3	25.57 Billion KRW	1759.92%
2022 Q2	-1.54 Billion KRW	84.83%
2021 Q3	-10.83 Billion KRW	2.41%
2021 Q2	-11.09 Billion KRW	-1.29%
2021 Q4	-17.26 Billion KRW	-59.39%
2021 Q1	-10.95 Billion KRW	0.0%
2021 FY	- KRW	16.74%
2020 FY	- KRW	-51.85%
2019 FY	- KRW	-65.68%
2018 FY	- KRW	-153.14%
2017 FY	- KRW	-176.82%
2016 FY	- KRW	0.0%

Peer EBITDA Comparison of ABL Bio Inc.

Name	EBITDA	EBITDA Difference
Sam Chun Dang Pharm. Co., Ltd	6.54 Billion KRW	67.864%
Hyundai Bioscience Co., Ltd.	-12.74 Billion KRW	116.507%
ST Pharm Co.,Ltd.	52.48 Billion KRW	95.99%
Cellid, Co., Ltd.	-7.68 Billion KRW	127.39%